Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.034
Neutral
RSI(14)
41.524
Neutral
STOCH(KDJ)(9,3,3)
33.855
Sell
ATR(14)
0.090
Low Volatility
CCI(14)
14.286
Neutral
Williams %R
61.905
Sell
TRIX(12,20)
-0.532
Sell
StochRSI(14)
24.900
Sell
Protalix Biotherapeutics Inc
PLX1.770USD
+0.040+2.31%
Market hours （ET）Quotes delayed by 15 min
142.20MMarket Cap
23.62P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Protalix Biotherapeutics Inc
Currency: USD Updated: 2025-12-19Key Insights
Protalix Biotherapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 100/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Protalix Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
12.500
Target Price
+618.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Protalix Biotherapeutics Inc Highlights
StrengthsRisks
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 53.40M.
Overvalued
The company’s latest PE is 23.08, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 12.24M shares, increasing 6.46% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.32M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.06.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Protalix Biotherapeutics Inc is 7.93, ranking 91/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.85M, representing a year-over-year decrease of 0.60%, while its net profit experienced a year-over-year decrease of 27.22%.
Score
Financials
6.78
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
5.54
Operational Efficiency
10.00
Growth Potential
9.80
Shareholder Returns
7.54
Protalix Biotherapeutics Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Protalix Biotherapeutics Inc is 6.20, ranking 130/158 in the Pharmaceuticals industry. Its current P/E ratio is 23.08, which is 188.32% below the recent high of 66.55 and 157.02% above the recent low of -13.16.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 100/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Protalix Biotherapeutics Inc is 8.00, ranking 56/158 in the Pharmaceuticals industry. The average price target for Protalix Biotherapeutics Inc is 12.50, with a high of 13.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
12.500
Target Price
+618.39%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Protalix Biotherapeutics Inc
PLX
1
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Protalix Biotherapeutics Inc is 5.95, ranking 134/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.84 and the support level at 1.63, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.768
Buy
MA10
1.775
Sell
MA20
1.761
Buy
MA50
2.021
Sell
MA100
1.913
Sell
MA200
1.951
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Protalix Biotherapeutics Inc is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 15.35%, representing a quarter-over-quarter decrease of 34.95%. The largest institutional shareholder is James Simons, holding a total of 1.32M shares, representing 1.64% of shares outstanding, with 9.51% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
HIR Investments Ltd
BlackRock Institutional Trust Company, N.A.
Bashan (Dror)
Geode Capital Management, L.L.C.
Rubin (Eyal)
Northern Trust Global Investments Limited
Stratos Wealth Partners, Ltd.
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Protalix Biotherapeutics Inc is 2.40, ranking 126/158 in the Pharmaceuticals industry. The company's beta value is -0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-0.25
VaR
+5.85%
240-Day Maximum Drawdown
+56.03%
240-Day Volatility
+80.02%
Return
Best Daily Return
60 days
+15.05%
120 days
+15.05%
5 years
+41.90%
Worst Daily Return
60 days
-22.50%
120 days
-22.50%
5 years
-40.48%
Sharpe Ratio
60 days
-0.51
120 days
+0.83
5 years
+0.06
Risk Assessment
Maximum Drawdown
240 days
+56.03%
3 years
+73.21%
5 years
+86.95%
Return-to-Drawdown Ratio
240 days
-0.40
3 years
+0.03
5 years
-0.15
Skewness
240 days
-2.45
3 years
-1.02
5 years
-0.23
Volatility
Realised Volatility
240 days
+80.02%
5 years
+80.71%
Standardised True Range
240 days
+7.18%
5 years
+6.04%
Downside Risk-Adjusted Return
120 days
+107.62%
240 days
+107.62%
Maximum Daily Upside Volatility
60 days
+65.84%
Maximum Daily Downside Volatility
60 days
+77.68%
Liquidity
Average Turnover Rate
60 days
+1.03%
120 days
+1.16%
5 years
--
Turnover Deviation
20 days
+5.78%
60 days
+48.55%
120 days
+66.64%
Peer Comparison
Pharmaceuticals
Protalix Biotherapeutics Inc
PLX
6.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Protalix Biotherapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Protalix Biotherapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Protalix Biotherapeutics Inc’s performance and outlook.
How do we generate the financial health score of Protalix Biotherapeutics Inc?
To generate the financial health score of Protalix Biotherapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Protalix Biotherapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Protalix Biotherapeutics Inc.
How do we generate the company valuation score of Protalix Biotherapeutics Inc?
To generate the company valuation score of Protalix Biotherapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Protalix Biotherapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Protalix Biotherapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Protalix Biotherapeutics Inc.
How do we generate the earnings forecast score of Protalix Biotherapeutics Inc?
To calculate the earnings forecast score of Protalix Biotherapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Protalix Biotherapeutics Inc’s future.
How do we generate the price momentum score of Protalix Biotherapeutics Inc?
When generating the price momentum score for Protalix Biotherapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Protalix Biotherapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Protalix Biotherapeutics Inc.
How do we generate the institutional confidence score of Protalix Biotherapeutics Inc?
To generate the institutional confidence score of Protalix Biotherapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Protalix Biotherapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Protalix Biotherapeutics Inc.
How do we generate the risk management score of Protalix Biotherapeutics Inc?
To assess the risk management score of Protalix Biotherapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Protalix Biotherapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Protalix Biotherapeutics Inc.
